Trials / Completed
CompletedNCT01458288
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GPCR Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-0054 | 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions) |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2011-10-24
- Last updated
- 2021-04-19
- Results posted
- 2015-01-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01458288. Inclusion in this directory is not an endorsement.